In a clinical trial led by University of Toronto researchers, an allogeneic stem cell–derived islet therapy (zimislecel) restored insulin production and ended severe hypoglycemia in adults with type 1 diabetes within a year of treatment.
This article was originally published on MedicalXpress.com